04-1570-I
Anti-RNA polymerase II subunit B1 (phospho-CTD Ser-7) Antibody, clone 4E12
culture supernatant, clone 4E12, from rat
别名:
DNA-directed RNA polymerase II subunit RPB1, RNA polymerase II subunit B1, DNA-directed RNA polymerase II subunit A, DNA-directed RNA polymerase III largest subunit, RNA-directed RNA polymerase II subunit RPB1
登录 查看组织和合同定价。
选择尺寸
关于此项目
UNSPSC Code:
12352203
NACRES:
NA.41
eCl@ss:
32160702
Clone:
4E12, monoclonal
Species reactivity:
mouse
Application:
ChIP
ELISA
western blot
ELISA
western blot
Technique(s):
ChIP: suitable
ELISA: suitable
western blot: suitable
ELISA: suitable
western blot: suitable
Citations:
16
Uniprot accession no.:
产品名称
Anti-RNA polymerase II subunit B1 (phospho-CTD Ser-7) Antibody, clone 4E12, culture supernatant, clone 4E12, from rat
biological source
rat
antibody form
culture supernatant
antibody product type
primary antibodies
clone
4E12, monoclonal
species reactivity
mouse
species reactivity (predicted by homology)
human (based on 100% sequence homology)
technique(s)
ChIP: suitable
ELISA: suitable
western blot: suitable
isotype
IgG1κ
NCBI accession no.
UniProt accession no.
shipped in
wet ice
target post-translational modification
phosphorylation (pSer7)
Quality Level
Gene Information
human ... POLR2B(5431)
Analysis Note
Evaluated by Western Blotting in untreated and lambda phosphatase treated NIH/3T3 cell lysate.
Western Blotting Analysis: A 1:2,000 dilution from a representative lot detected RNA polymerase II subunit B1 (phospho-CTD Ser-7) in 10 μg of untreated NIH/3T3 cell lysate.
Western Blotting Analysis: A 1:2,000 dilution from a representative lot detected RNA polymerase II subunit B1 (phospho-CTD Ser-7) in 10 μg of untreated NIH/3T3 cell lysate.
Application
Anti-RNA polymerase II subunit B1 (phospho-CTD Ser-7) Antibody, clone 4E12 is a highly specific rat monoclonal antibody & that targets RNA Polymerase & has been tested in western blotting.
Chromatin Immunoprecipitation Analysis: A representative lot was used by an independent laboratory to immunoprecipitate RNA polymerase II subunit B1 (phospho-CTD Ser-5) in ChIP (Chapman, R., et al. (2007). Science. 318(5857):1780-1782.).
Demonstrated to react with human RBP1 in Ni et al., 2011. Transcription 2:5, 237-242
Demonstrated to react with human RBP1 in Ni et al., 2011. Transcription 2:5, 237-242
Biochem/physiol Actions
Demonstrated to react with human RBP1 in Ni et al., 2011. Transcription 2:5, 237-242
This antibody recognizes RNA polymerase II subunit B1 phosphorylated at Ser7 of the C-terminal domain (CTD).
General description
RPB1 (RNA polymerase II subunit B1) is the catalytic component of RNA polymerase II which synthesizes mRNA and non-coding RNAs. During transcription, elongation is influenced by the phosphorylation status of the C-terminal domain (CTD) of RPB1, which acts as an assembly platform for factors regulating transcription initiation, elongation, termination and mRNA processing. Phosphorylation occurs mainly at residues ′Ser-2′ and ′Ser-5′ of the tandem 7 residue repeats in the C-terminal domain (CTD), which activates Pol II. This phosphorylation also can occur at ′Ser-7′ of the heptapepdtide repeat. This antibody recognizes the ′Ser-7′ CTD residue of RPB1.
~220 kDa observed
Immunogen
Epitope: Phosphorylated Ser7 of the C-terminal domain (CTD)
Ovalbumin-conjugated linear peptide corresponding to human RNA polymerase II subunit B1 phosphorylated at Ser7 of the C-terminal domain (CTD).
Other Notes
Replaces: 04-1570
Physical form
Rat monoclonal IgG1κ with 0.05% sodium azide.
未找到合适的产品？
试试我们的产品选型工具.
存储类别
10 - Combustible liquids
wgk
WGK 1
Emily Brookes et al.
Cell stem cell, 10(2), 157-170 (2012-02-07)
Polycomb repressor complexes (PRCs) are important chromatin modifiers fundamentally implicated in pluripotency and cancer. Polycomb silencing in embryonic stem cells (ESCs) can be accompanied by active chromatin and primed RNA polymerase II (RNAPII), but the relationship between PRCs and RNAPII
Tanaz Sharifnia et al.
Nature medicine, 25(2), 292-300 (2019-01-22)
Chordoma is a primary bone cancer with no approved therapy1. The identification of therapeutic targets in this disease has been challenging due to the infrequent occurrence of clinically actionable somatic mutations in chordoma tumors2,3. Here we describe the discovery of
Jing Gao et al.
Haematologica (2021-06-25)
Despite significant progress in the treatment of patients with diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL), prognosis of patients with relapsed disease remains poor due to the emergence of drug resistance and subsequent disease progression. Identification of
Jiajun Zhang et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 26(11), 2681-2692 (2020-01-16)
Malignancy of cancer cells depends on the active transcription of tumor-associated genes. Recently, unique clusters of transcriptional enhancers, termed super-enhancers, have been reported to drive the expression of genes that define cell identity. In this study, we characterized specific super-enhancer-associated
Xiaohong Zhao et al.
Cell reports, 34(11), 108870-108870 (2021-03-18)
Ibrutinib, a bruton's tyrosine kinase (BTK) inhibitor, provokes robust clinical responses in aggressive mantle cell lymphoma (MCL), yet many patients relapse with lethal Ibrutinib-resistant (IR) disease. Here, using genomic, chemical proteomic, and drug screen profiling, we report that enhancer remodeling-mediated
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持